Literature DB >> 21194727

The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: relationship of heterogeneous nuclear ribonucleoproteins with prognosis.

Nicholas R Hope1, Graeme I Murray.   

Abstract

The heterogeneous nuclear ribonucleoproteins are a group of RNA-binding proteins with a range of key cellular functions, which are dysregulated in tumorigenesis including regulation of translational and RNA processing. The aims of this study were to define the heterogeneous nuclear ribonucleoprotein expression profile in primary and metastatic colorectal cancer and to establish the clinicopathologic significance of this expression. A tissue microarray containing 515 primary colorectal cancers, 224 lymph node metastasis of colorectal cancer, and 50 normal colon samples was immunostained for 6 heterogeneous nuclear ribonucleoproteins. Heterogeneous nuclear ribonucleoprotein I, heterogeneous nuclear ribonucleoprotein K, and heterogeneous nuclear ribonucleoprotein L displayed the most frequent strong immunoreactivity in primary colorectal tumor samples. Heterogeneous nuclear ribonucleoprotein A1 (P < .001) and heterogeneous nuclear ribonucleoprotein U (P = .003) showed significant alterations in nuclear expression in tumors compared with normal colonic epithelium, whereas heterogeneous nuclear ribonucleoprotein A1 (P = .001), heterogeneous nuclear ribonucleoprotein I (P < .001), and heterogeneous nuclear ribonucleoprotein K (P < .001) all showed significant aberrant cytoplasmic immunoreactivity in tumor cells. There were also significant differences in cytoplasmic immunoreactivity between the primary tumor and the corresponding lymph node metastasis for heterogeneous nuclear ribonucleoprotein A1 (P = .001), heterogeneous nuclear ribonucleoprotein I (P < .001), and heterogeneous nuclear ribonucleoprotein K (P = .001). Nuclear heterogeneous nuclear ribonucleoprotein H (χ(2) = 72.1; P < .001), cytoplasmic heterogeneous nuclear ribonucleoprotein I (χ(2) = 28.1; P < .001), and cytoplasmic heterogeneous nuclear ribonucleoprotein K (χ(2) = 13.2; P = .04) all showed significant associations with tumor stage. There was a significant relationship between strong nuclear heterogeneous nuclear ribonucleoprotein H expression and survival (χ(2) = 14.97; P < .001). This study has defined the expression profile of heterogeneous nuclear ribonucleoproteins in colorectal cancer and shown that there are significant alterations in both expression and subcellular localization of individual heterogeneous nuclear ribonucleoproteins in this type of tumor.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21194727     DOI: 10.1016/j.humpath.2010.08.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  34 in total

1.  Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p.

Authors:  Chang Hoon Shin; Hong Lee; Hye Ree Kim; Kyung Hee Choi; Je-Gun Joung; Hyeon Ho Kim
Journal:  Cell Death Differ       Date:  2017-07-14       Impact factor: 15.828

2.  Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation.

Authors:  Michael Jewer; Scott D Findlay; Lynne-Marie Postovit
Journal:  J Cell Commun Signal       Date:  2012-10-09       Impact factor: 5.782

3.  Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer.

Authors:  Feng Wang; Peng Zhang; Chenzhang Shi; Yongzhi Yang; Huanlong Qin
Journal:  Med Oncol       Date:  2011-08-23       Impact factor: 3.064

4.  Regulation of Mcl-1 alternative splicing by hnRNP F, H1 and K in breast cancer cells.

Authors:  Alison Tyson-Capper; Hannah Gautrey
Journal:  RNA Biol       Date:  2018-12-04       Impact factor: 4.652

5.  Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases.

Authors:  Akio Shiomi; Masatoshi Kusuhara; Takashi Sugino; Teiichi Sugiura; Keiichi Ohshima; Takeshi Nagashima; Kenichi Urakami; Masakuni Serizawa; Hideyuki Saya; Ken Yamaguchi
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

6.  Identification and functional characterization of nuclear mortalin in human carcinogenesis.

Authors:  Jihoon Ryu; Zeenia Kaul; A-Rum Yoon; Ye Liu; Tomoko Yaguchi; Youjin Na; Hyo Min Ahn; Ran Gao; Il-Kyu Choi; Chae-Ok Yun; Sunil C Kaul; Renu Wadhwa
Journal:  J Biol Chem       Date:  2014-07-10       Impact factor: 5.157

7.  Role and molecular mechanism of heterogeneous nuclear ribonucleoprotein K in tumor development and progression.

Authors:  Jing Lu; Feng-Hou Gao
Journal:  Biomed Rep       Date:  2016-03-29

8.  The proteomics of colorectal cancer: identification of a protein signature associated with prognosis.

Authors:  Donna O'Dwyer; Lynda D Ralton; Aisling O'Shea; Graeme I Murray
Journal:  PLoS One       Date:  2011-11-18       Impact factor: 3.240

9.  SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells.

Authors:  Hannah Gautrey; Claire Jackson; Anna-Lena Dittrich; David Browell; Thomas Lennard; Alison Tyson-Capper
Journal:  RNA Biol       Date:  2015-09-14       Impact factor: 4.652

Review 10.  Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis.

Authors:  Jun Wang; Yan Guo; Huili Chu; Yaping Guan; Jingwang Bi; Baocheng Wang
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.